ADMA Biologics (ADMA) Short Interest Ratio & Short Volume $17.40 -0.50 (-2.79%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ADMA Biologics Short Interest DataADMA Biologics (ADMA) has a short interest of 12.91 million shares. This marks a -9.34% decrease in short interest from the previous month. The short interest ratio (days to cover) is 2.6, indicating that it would take 2.6 days of the average trading volume of 3.57 million shares to cover all short positions.Current Short Interest12,910,000 sharesPrevious Short Interest14,240,000 sharesChange Vs. Previous Month-9.34%Dollar Volume Sold Short$259.62 millionShort Interest Ratio2.6 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares236,390,000 sharesPercentage of Shares Shorted5.46%Today's Trading Volume6,941,298 sharesAverage Trading Volume3,573,030 sharesToday's Volume Vs. Average194% Short Selling ADMA Biologics? Sign up to receive the latest short interest report for ADMA Biologics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartADMA Short Interest Over TimeADMA Days to Cover Over TimeADMA Percentage of Float Shorted Over Time Ad Weiss RatingsBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office.This could be his favorite coin. ADMA Biologics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/202412,910,000 shares $259.62 million -9.3%N/A2.6 $20.11 11/15/202414,240,000 shares $271.13 million -6.3%N/A2.8 $19.04 10/31/202415,200,000 shares $247.91 million -5.4%N/A2.9 $16.31 10/15/202416,070,000 shares $266.44 million -5.9%N/A3.1 $16.58 9/30/202417,080,000 shares $341.43 million +37.5%N/A3.6 $19.99 9/15/202412,420,000 shares $224.68 million +30.7%N/A2.6 $18.09 Get the Latest News and Ratings for ADMA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter. 8/31/20249,500,000 shares $164.45 million +5.3%N/A2.6 $17.31 8/15/20249,020,000 shares $158.66 million +3.1%N/A2.6 $17.59 7/31/20248,750,000 shares $107.45 million +5.7%N/A2.5 $12.28 7/15/20248,280,000 shares $110.87 million +13.9%N/A2.6 $13.39 6/30/20247,270,000 shares $81.28 million -23.0%N/A2.5 $11.18 6/15/20249,440,000 shares $100.35 million +2.5%N/A3.4 $10.63 5/31/20249,210,000 shares $87.96 million +9.1%N/A3.3 $9.55 5/15/20248,440,000 shares $76.80 million -3.2%N/A2.9 $9.10 4/30/20248,720,000 shares $56.85 million +7.5%N/A3.4 $6.52 4/15/20248,110,000 shares $48.50 million +11.3%N/A3.2 $5.98 3/31/20247,290,000 shares $48.11 million -8.8%N/A2.7 $6.60 3/15/20247,990,000 shares $47.86 million +18.9%N/A3 $5.99 2/29/20246,720,000 shares $36.02 million +9.3%N/A2.6 $5.36 2/15/20246,150,000 shares $33.21 million -10.1%N/A2.9 $5.40 1/31/20246,840,000 shares $35.50 million -14.8%N/A3.2 $5.19 1/15/20248,030,000 shares $40.07 million +19.0%N/A3.7 $4.99 12/31/20236,750,000 shares $30.51 million -13.6%N/A3.4 $4.52 12/15/20237,810,000 shares $32.80 million -10.2%N/A4.2 $4.20 11/30/20238,700,000 shares $32.19 million -6.3%N/A4.9 $3.70 11/15/20239,280,000 shares $35.26 million -3.1%N/A4.8 $3.80 10/31/20239,580,000 shares $32.38 million +3.9%N/A4.1 $3.38 10/15/20239,220,000 shares $29.60 million +3.3%N/A4.2 $3.21 9/30/20238,930,000 shares $31.97 million +2.8%N/A4.1 $3.58 9/15/20238,690,000 shares $32.41 million -1.9%N/A4.1 $3.73 8/31/20238,860,000 shares $34.11 million -1.7%N/A4 $3.85 8/15/20239,010,000 shares $40.91 million +8.4%N/A4.2 $4.54 7/31/20238,310,000 shares $34.49 million -2.4%N/A4.1 $4.15 7/15/20238,510,000 shares $30.38 million +2.7%N/A4.2 $3.57 6/30/20238,290,000 shares $30.59 million -19.8%N/A3.9 $3.69 6/15/202310,340,000 shares $41.26 million -1.2%N/A4.6 $3.99 5/31/202310,460,000 shares $42.57 million -6.4%N/A4.4 $4.07 5/15/202311,170,000 shares $46.80 million -1.2%N/A4.6 $4.19 4/30/202311,310,000 shares $37.89 million -2.8%N/A5.1 $3.35 4/15/202311,640,000 shares $37.02 million -6.8%N/A4.9 $3.18Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. 3/31/202312,490,000 shares $41.34 million +14.4%N/A5.1 $3.31 3/15/202310,920,000 shares $34.18 million +0.8%N/A4.4 $3.13 2/28/202310,830,000 shares $38.45 million -6.2%N/A3.8 $3.55 2/15/202311,550,000 shares $41.35 million -9.7%N/A3.9 $3.58 1/31/202312,790,000 shares $47.20 million +6.1%N/A3.8 $3.69 1/15/202312,050,000 shares $40.97 million -5.3%N/A3.7 $3.40 12/30/202212,720,000 shares $49.35 million +1.8%N/A4 $3.88 12/15/202212,500,000 shares $44.50 million -37.4%N/A3.7 $3.56 11/30/202219,980,000 shares $66.73 million -8.1%N/A6 $3.34 11/15/202221,740,000 shares $70.44 million -15.9%N/A7.2 $3.24 10/31/202225,860,000 shares $72.93 million +0.2%N/A9.1 $2.82 10/15/202225,820,000 shares $67.65 million -6.3%N/A9.5 $2.62 9/30/202227,560,000 shares $66.97 million +6.0%N/A10.4 $2.43 9/15/202225,990,000 shares $70.43 million -2.0%N/A9 $2.71 8/31/202226,520,000 shares $71.60 million -6.2%N/A9.8 $2.70 8/15/202228,270,000 shares $68.13 million -1.7%N/A10.7 $2.41 7/31/202228,760,000 shares $61.55 million +0.1%N/A11.1 $2.14 7/15/202228,730,000 shares $66.08 million +1.3%N/A10.2 $2.30 6/30/202228,360,000 shares $56.15 million +11.0%N/A9.8 $1.98 6/15/202225,540,000 shares $51.85 million +1.0%N/A8.1 $2.03 5/31/202225,300,000 shares $51.87 million +5.4%N/A9.3 $2.05 5/15/202224,010,000 shares $42.26 million +4.5%N/A9.2 $1.76 4/30/202222,980,000 shares $42.28 million +3.1%N/A9.1 $1.84 4/15/202222,300,000 shares $44.82 million +10.1%N/A9.3 $2.01 3/31/202220,250,000 shares $37.06 million +25.0%N/A8.8 $1.83 3/15/202216,200,000 shares $25.11 million +10.7%N/A8.2 $1.55 2/28/202214,640,000 shares $23.57 million +4.4%N/A7.4 $1.61 2/15/202214,020,000 shares $23.41 million +36.0%N/A7.2 $1.67 1/31/202210,310,000 shares $14.95 million +1.2%N/A4.6 $1.45 1/15/202210,190,000 shares $14.27 million -4.1%N/A4.5 $1.40 12/31/202110,620,000 shares $14.97 million +6.6%N/A4.1 $1.41 12/15/20219,960,000 shares $12.75 million -1.2%N/A4 $1.28 11/30/202110,080,000 shares $13.91 million -9.7%N/A4.1 $1.38 11/15/202111,160,000 shares $17.30 million -7.4%N/A3.5 $1.55 10/29/202112,050,000 shares $15.54 million +4.4%N/A3.5 $1.29 10/15/202111,540,000 shares $12.69 million +10.5%N/A3.5 $1.10 9/30/202110,440,000 shares $11.80 million -9.9%8.3%3.6 $1.13 9/15/202111,590,000 shares $13.91 million -5.2%9.2%3.7 $1.20 8/31/202112,220,000 shares $16.37 million -3.3%9.7%3.9 $1.34 8/13/202112,640,000 shares $18.83 million -5.1%10.0%4.9 $1.49 7/30/202113,320,000 shares $20.65 million +14.2%10.6%6.3 $1.55 7/15/202111,660,000 shares $17.26 million +14.8%9.2%1.8 $1.48 6/30/202110,160,000 shares $16.26 million -16.9%8.1%1.5 $1.60 6/15/202112,220,000 shares $21.75 million +11.4%9.7%1.8 $1.78 5/28/202110,970,000 shares $19.20 million -0.6%8.7%1.6 $1.75 5/14/202111,040,000 shares $17.88 million -21.4%N/A1.6 $1.62 4/30/202114,050,000 shares $28.80 million +36.0%N/A1.9 $2.05 4/15/202110,330,000 shares $17.77 million +2.6%N/A2.9 $1.72 3/31/202110,070,000 shares $17.22 million +17.9%N/A2.8 $1.71 3/15/20218,540,000 shares $18.10 million +4.4%N/A2.3 $2.12Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. 2/26/20218,180,000 shares $19.22 million -6.5%N/A2 $2.35 2/12/20218,750,000 shares $25.29 million -9.3%N/A2.2 $2.89 1/29/20219,650,000 shares $20.94 million -13.0%N/A2.6 $2.17 1/15/202111,090,000 shares $23.40 million -4.3%N/A3.4 $2.11 12/31/202011,590,000 shares $23.30 million -3.2%N/A4 $2.01 12/15/202011,970,000 shares $25.38 million +0.2%N/A3.8 $2.12 11/30/202011,950,000 shares $22.71 million -2.3%N/A4.1 $1.90 11/15/202012,230,000 shares $23.48 million -5.4%N/A3.8 $1.92 10/30/202012,930,000 shares $26.25 million -8.3%N/A2.7 $2.03 10/15/202014,100,000 shares $32.29 million +1.4%N/A2.2 $2.29 9/30/202013,910,000 shares $33.24 million +4.1%N/A2.2 $2.39 9/15/202013,360,000 shares $31.26 million +0.4%N/A2.3 $2.34 8/31/202013,310,000 shares $33.94 million +12.0%N/A2.3 $2.55 8/14/202011,880,000 shares $37.07 million +21.1%N/A2 $3.12 7/31/20209,810,000 shares $35.02 million +1.7%N/A2.3 $3.57 7/15/20209,650,000 shares $27.99 million +0.9%N/A3.5 $2.90 6/30/20209,560,000 shares $28.01 million +3.8%N/A3.6 $2.93 6/15/20209,210,000 shares $28.46 million -7.5%N/A3.3 $3.09 5/29/20209,960,000 shares $32.77 million +2.9%N/A3.2 $3.29 5/15/20209,680,000 shares $25.36 million +10.5%N/A3.3 $2.62 4/30/20208,760,000 shares $25.84 million +2.9%N/A2.9 $2.95 4/15/20208,510,000 shares $23.40 million +17.5%N/A3.2 $2.75 3/31/20207,240,000 shares $22.15 million +4.1%N/A2.9 $3.06 3/13/20206,958,500 shares $19.00 million +29.8%N/A2.4 $2.73 2/28/20205,360,000 shares $16.40 million +11.2%N/A3.5 $3.06 2/14/20204,820,000 shares $12.48 million +3.7%N/A4.1 $2.59 1/31/20204,650,000 shares $14.83 million -10.9%10.3%4.9 $3.19 1/15/20205,220,000 shares $18.74 million -0.8%11.5%7.2 $3.59 12/31/20195,260,000 shares $22.41 million +2.9%11.6%7.3 $4.26 ADMA Short Interest - Frequently Asked Questions What is ADMA Biologics' current short interest? Short interest is the volume of ADMA Biologics shares that have been sold short but have not yet been closed out or covered. As of November 30th, traders have sold 12,910,000 shares of ADMA short. Learn More on ADMA Biologics' current short interest. What is a good short interest ratio for ADMA Biologics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ADMA shares currently have a short interest ratio of 3.0. Learn More on ADMA Biologics's short interest ratio. Is ADMA Biologics' short interest increasing or decreasing? ADMA Biologics saw a decrease in short interest in November. As of November 30th, there was short interest totaling 12,910,000 shares, a decrease of 9.3% from the previous total of 14,240,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does ADMA Biologics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to ADMA Biologics: BeiGene, Ltd. (1.36%), Moderna, Inc. (11.90%), Viatris Inc. (1.78%), Summit Therapeutics Inc. (2.28%), Genmab A/S (0.32%), Dr. Reddy's Laboratories Limited (1.32%), Sarepta Therapeutics, Inc. (6.09%), Catalent, Inc. (8.12%), Vaxcyte, Inc. (8.85%), Qiagen (1.68%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short ADMA Biologics stock? Short selling ADMA is an investing strategy that aims to generate trading profit from ADMA Biologics as its price is falling. ADMA shares are trading down $0.50 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against ADMA Biologics? A short squeeze for ADMA Biologics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ADMA, which in turn drives the price of the stock up even further. How often is ADMA Biologics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ADMA, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies BGNE Short Squeeze MRNA Short Squeeze VTRS Short Squeeze SMMT Short Squeeze GMAB Short Squeeze RDY Short Squeeze SRPT Short Squeeze CTLT Short Squeeze PCVX Short Squeeze QGEN Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ADMA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ADMA Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADMA Stock Alerts